# Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

> **NCT01640912** · PHASE1 · COMPLETED · sponsor: **RXi Pharmaceuticals, Corp.** · enrollment: 15 (actual)

## Conditions studied

- Cicatrix
- Scar Prevention

## Interventions

- **DRUG:** RXI-109
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01640912
- **Lead sponsor:** RXi Pharmaceuticals, Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640912, "Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01640912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*